New cell therapy aims to wipe out hidden lymphoma
NCT ID NCT07006012
First seen Apr 16, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This early study tests a new cell therapy called RGL-305 in 12 adults with lymphoma who still have signs of disease after standard treatment. The goal is to see if it is safe and can help control the cancer. Participants receive a single infusion of the therapy and are monitored for side effects and how long the cells last in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA PATIENTS WITH COMPLETE RESPONSE (CR) OR PARTIAL RESPONSE (PR) AFTER STANDARD TREATMENT HAD A POSITIVE MINIMAL RESIDUAL LESION (MRD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.